Results 11 to 20 of about 220,963 (356)

Acute lymphoblastic leukemia [PDF]

open access: yesPediatric Blood & Cancer, 2021
AbstractThe survival of patients with acute lymphoblastic leukemia (ALL) has improved significantly with the use of intensive multimodality treatment regimens including chemotherapy, high‐dose chemotherapy and stem cell rescue, and radiation therapy when indicated.
John Han‐Chih Chang   +4 more
openaire   +2 more sources

Acute Lymphoblastic Leukemia [PDF]

open access: yesJournal of the National Comprehensive Cancer Network, 2012
The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment ...
Joseph C, Alvarnas   +26 more
openaire   +2 more sources

Relapsed Acute Lymphoblastic Leukemia

open access: yesIndian Journal of Pediatrics, 2023
AbstractOutcomes for children with acute lymphoblastic leukemia (ALL) have improved worldwide to >85%. For those who relapse, outcomes have remained static at ~50% making relapsed acute lymphoblastic leukemia one of the leading causes of death in childhood cancers.
Sidhu, Jasmeet   +3 more
openaire   +3 more sources

Adult Acute Lymphoblastic Leukemia [PDF]

open access: yesMayo Clinic Proceedings, 2005
Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated into the recognition of several subgroups of ALL and the institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities.
Shilpa, Paul   +2 more
openaire   +3 more sources

Features of Pavement Damage due to Hyogo-ken Nanbu Earthquake [PDF]

open access: yes, 1997
Translocation of the LYL1 oncogene are rare in T-cell acute lymphoblastic leukemia, whereas the homologous TAL1 gene is rearranged in approximately 20% of patients.
Buijs-Gladdines, Jessica   +5 more
core   +3 more sources

The molecular basis of T cell acute lymphoblastic leukemia [PDF]

open access: yes, 2012
T cell acute lymphoblastic leukemias (T-ALLs) arise from the malignant transformation of hematopoietic progenitors primed toward T cell development, as result of a multistep oncogenic process involving constitutive activation of NOTCH signaling and ...
Adolfo Ferrando   +23 more
core   +1 more source

MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia

open access: yesHaematologica, 2014
T-cell acute lymphoblastic leukemia arises from the leukemic transformation of developing thymocytes and results from cooperative genetic lesions. Inactivation of the PHF6 gene is frequently observed in T-cell acute lymphoblastic leukemia, suggesting an ...
Evelien Mets   +15 more
doaj   +1 more source

Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report

open access: yesJournal of Medical Case Reports, 2021
Background The occurrence of acute leukemia in patients with sickle cell anemia is uncommon. The Philadelphia chromosome is the hallmark of chronic myeloid leukemia.
Ibrahim O. Ahmed   +4 more
doaj   +1 more source

Oral health management in children with acute lymphoblastic leukemia

open access: yes口腔疾病防治, 2021
Acute lymphoblastic leukemia is the most common type of leukemia in children. In recent years, the treatment and prognosis of acute lymphoblastic leukemia in children have improved significantly. However, acute lymphoblastic leukemia itself and treatment
TANG Yawen   +4 more
doaj   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

open access: yes, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy